SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is rallying following a significant order for its wafer-level burn-in systems from a major silicon photonics customer, signaling a transition toward high-volume production for AI data center infrastructure. The stock remains a heavily debated AI infrastructure play, with the community actively split between bulls betting on multi-year growth in chip testing demand and bears pointing to high valuation multiples relative to current revenue.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is experiencing a historic sell-off as a revenue miss and a shift in enterprise spending toward AI infrastructure over software and consulting trigger widespread investor concern. The community is actively debating whether the 25% drop is an extreme overreaction to a short-term spending shift or a fundamental breakdown of the company's long-term business model.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is seeing intense volatility following its recent U.S. ADR debut, with the community fiercely debating whether the stock's significant premium over its South Korean listing signals a structural re-rating or a temporary bubble ripe for an arbitrage correction. Investors remain divided between bullish sentiment fueled by AI memory demand and HBM supply constraints, and bearish concerns regarding the impact of Korean market leverage, margin calls, and the potential for a technical rug-pull following the IPO excitement.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing intense volatility and downward pressure as investors weigh concerns over heavy capital expenditure and debt against its significant cloud and AI backlog. Community sentiment remains deeply divided, with some traders actively betting on a short squeeze or long-term value recovery, while others express frustration over the lack of communication from leadership during the ongoing slide.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending following an earnings report that featured strong revenue performance but left investors divided over the company's valuation and ARR growth expectations. While the community is actively debating whether the stock's massive rally is due for a healthy consolidation or if the cybersecurity sector remains a critical long-term AI infrastructure play, sentiment is split between those viewing the pullback as a buying opportunity and others concerned about its premium price-to-earnings multiple.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is currently trending as investors monitor its transition to a commercial-stage oncology company following the FDA approval of its breast cancer therapy, Revtorpyk. While the market is debating the short-term price action and potential for institutional buyouts, the community remains focused on the drug's strong efficacy data and the company's improved financial position to execute its commercial launch.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending following a strategic shift to discontinue internal drug discovery and close its Alabama facility, a move investors are interpreting as a potential catalyst for an acquisition or buyout. The community is actively debating the company's path to profitability, with many highlighting the stock's high short interest and debating whether this restructuring signals a sale or a long-term pivot to external innovation.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing a surge in social media activity driven by anticipation of upcoming Phase 3 trial milestones and potential Russell 2000 index inclusion, which investors believe will bring significant institutional demand. The community is actively debating the stock's long-term valuation compared to sector peers and monitoring for signs of major pharma partnerships, while many remain focused on the potential for a gamma squeeze or a strategic re-rating.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors weigh recent platform developments and expansion efforts against persistent volatility, with the community actively debating whether current price levels represent a significant accumulation opportunity or continued downside risk. Discussion is centered on the potential impact of long-term infrastructure milestones and enterprise adoption, balanced against concerns regarding supply dilution and the need for sustained real-world usage.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is currently trending as speculative takeover interest intensifies, driven by market chatter linking the studio to potential acquirers like Legendary Entertainment. Investors and the community are actively debating the company's valuation against its deep content library, with many viewing the stock as an attractive acquisition target in a consolidating media landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 468,369...

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 414,235 shares, a decrease of 14.2% from the March 15th total of 483,060 shares. Based on an average daily trading...

CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw

Rodman & Renshaw upgraded CAMP4 Therapeutics to a "strong-buy" rating in a research report on Tuesday...

CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H

CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs) and provided an update on its lead central nervous system (CNS) program...

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings...

Camp4 Therapeutics Earnings Review: Q4 Summary

CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why

CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.21	--	--	N/A
Q1 '26	-$0.21	-$0.32	-52.38%	MISSED
Q4 '25	-$0.47	-$0.86	-81.81%	MISSED
Q3 '25	-$0.48	-$0.55	-14.98%	MISSED
Q2 '25	-$0.67	-$0.62	7.81%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAMPCalamp Corp.

Latest Earnings Results: Q1 '26

Historical Earnings

Latest CAMP News